ImmunityBio, Inc

NEWS

Business

ImmunityBio Backslides while Rigel and Amneal also Reveal Job Cuts (Updated)

ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.

October 11, 2022

·

3 min read

·

JOBS

IN THE PRESS

Press Releases

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025

·

14 min read

Press Releases

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025

·

14 min read

Press Releases

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

April 29, 2025

·

12 min read

Press Releases

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

April 15, 2025

·

12 min read

Press Releases

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

April 8, 2025

·

5 min read

Press Releases

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

April 7, 2025

·

7 min read

Press Releases

ImmunityBio to Host Investor Day

March 26, 2025

·

6 min read

Press Releases

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

March 13, 2025

·

13 min read

Press Releases

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

March 3, 2025

·

18 min read

Press Releases

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

February 19, 2025

·

11 min read